1.
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised,...
by Sax, Paul E, Dr Prof
The Lancet (British edition), 2015, Vol.385 (9987), p.2606-2615
2.
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
by Molina, Jean-Michel, Dr, Prof
The Lancet (British edition), 2011, Vol.378 (9787), p.238-246
3.
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir i...
by Arribas, Jose R, Dr
The Lancet infectious diseases, 2014, Vol.14 (7), p.581-589
4.
Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients
by Mocroft, Amanda
AIDS (London), 2010, Vol.24 (11), p.1667-1678
5.
RMP-02/MTN-006: A Phase 1 Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Tenofovir 1% Gel Compared with Oral Tenofovir Disoproxil Fumarate
by Anton, Peter A.
AIDS research and human retroviruses, 2012, Vol.28 (11), p.1412-1421
6.
Association of tenofovir exposure with kidney disease risk in HIV infection
by SCHERZER, Rebecca
AIDS (London), 2012, Vol.26 (7), p.867-875
7.
Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents
by BEDIMO, Roger
AIDS (London), 2012, Vol.26 (7), p.825-831
8.
Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis
by Solomon, Marc M
AIDS (London), 2014, Vol.28 (6), p.851-859
9.
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/ emtricitabine with lopinavir/ritonavir for initial HIV treatment
by SMITH, Kimberly Y
AIDS (London), 2009, Vol.23 (12), p.1547-1556
10.
Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir
by LABARGA, Pablo
AIDS (London), 2009, Vol.23 (6), p.689-696
11.
Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase...
by Baeten, Jared M, Prof
The Lancet infectious diseases, 2014, Vol.14 (11), p.1055-1064
12.
Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B
by Patterson, S J
Gut, 2011, Vol.60 (2), p.247-254
13.
Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons
by CHOI, Andy I
AIDS (London), 2011, Vol.25 (10), p.1289-1298
14.
Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009
by Abgrall, Sophie
AIDS (London), 2013, Vol.27 (5), p.803-813
15.
Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT3 VIN): a multicentre, open-label, randomised, phase 2 trial
by Tristram, Amanda, MD
The lancet oncology, 2014, Vol.15 (12), p.1361-1368
16.
Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B
by Lai, Ching-Lung
Gut, 2014, Vol.63 (6), p.996-1004
17.
Determination of glyphosate and AMPA in blood and urine from humans: About 13 cases of acute intoxication
by Zouaoui, K
Forensic science international, 2013, Vol.226 (1), p.e20-e25
18.
Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations
by RODRIGUEZ-NOVOA, Sonia
AIDS (London), 2010, Vol.24 (7), p.1064-1066
19.
Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up
by NISHIJIMA, Takeshi
AIDS (London), 2014, Vol.28 (13), p.1903-1910
20.
Impact of Switching From Zidovudine to Tenofovir Disoproxil Fumarate on Bone Mineral Density and Markers of Bone Metabolism in Virologically Suppressed HIV-1 Infected Patients; A S...
by Cotter, Aoife G
The journal of clinical endocrinology and metabolism, 2013, Vol.98 (4), p.1659-1666
